Stock

Q32 Bio

QTTB

Biotechnology · Healthcare

Also trades as: 0T6G.L GBP 0.08 (+5.41%)

Price

$8.34

+0.25 (+3.09%)

Market Cap

$248.2M

Exchange

NASDAQ

Winston Score

Winston is serious

Mixed quality — meaningful strengths and weaknesses.

Data as of Oct 10, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality

Weak

7/30

Growth

Mixed

9/20

Cash Flow

Weak

0/10

Stability

Exceptional

10/10

Valuation

Good

6/10

Ownership

Good

10/15

Dividends

Not counted

n/a

42 of 95 counted points = Winston Score 44. Pillars marked n/a do not apply to this company and are left out of the total.

Track this stock — start free trial

Share count rising — dilution

+3.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 11.9M (2021) → 12.3M (2025)

§Winston Score History

The full picture

Q32 Bio is a small biotechnology company focused on developing drugs that treat diseases caused by an overactive immune system. Its main focus is on conditions like atopic dermatitis (a severe form of eczema) and other inflammatory diseases. The company is working on experimental medicines that have not yet been approved, so it does not sell products to regular customers yet.

Q32 Bio makes almost no revenue from product sales right now. Instead, it funds its work through partnerships, grants, and money raised from investors. It operates primarily in the United States and has a market value of around $200 million, which is small even by biotech standards. The company's main risk is that its drugs must still pass clinical trials and win approval from the FDA before they can be sold — a process that is expensive, slow, and often fails.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

Data not available

Profit after running costs

Operating Margin

N/A

Data not available

Return on the money invested

ROCE

19.4%

Strong — 19.4% return on capital

ROIC between 15% and 25%. Every dollar invested in the business earns 15 to 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

Data not available

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

7/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

-46%

Weak — only -46% of profit becomes cash

Spare cash per sale

FCF Margin

-36.9%

Burning cash (-36.9%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.04

Conservative — low debt load (0.04)

Covers its interest

Interest Cover

30.66x

Comfortably covers interest (30.7x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

2.7x

Attractive valuation — P/E 2.7

P/E under 10. The price tag is small relative to last year's profit.

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial